LDL-associated apolipoprotein J and lysozyme are associated with atherogenic properties of LDL found in type 2 diabetes and the metabolic syndrome

Journal of Internal Medicine

Volumn 269, Issue 3, 2011, Pages 306-321

  Pettersson, C ^a   Karlsson, H ^b   Stahlman M ^a   Larsson, T ^a   Fagerberg, B ^a   Lindahl, M ^b   Wiklund, O ^a   Boren J ^a   Fogelstrand, L ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

ApoJ; Lysozyme; Metabolic syndrome; Proteomics; Small dense LDL; Type 2 diabetes

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; C REACTIVE PROTEIN; CHOLESTEROL; CLUSTERIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN; LYSOZYME; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

CHOLESTEROL; CHROMATOGRAPHY, GEL; CLUSTERIN; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LIPOPROTEINS, LDL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MURAMIDASE;

EID: 79951685847     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2010.02292.x     Document Type: Article

References (46)

1. Lundstam U, Herlitz J, Karlsson T, Linden T, Wiklund O. Serum lipids, lipoprotein(a) level, and apolipoprotein(a) isoforms as prognostic markers in patients with coronary heart disease. J Intern Med 2002; 251: 111-8.
2. St-Pierre AC, Cantin B, Dagenais GR et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005; 25: 553-9.
3. Boren J, Lee I, Zhu W, Arnold K, Taylor S, Innerarity TL. Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100. J Clin Invest 1998; 101: 1084-93.
4. Davidsson P, Hulthe J, Fagerberg B et al. A proteomic study of the apolipoproteins in LDL subclasses in patients with the metabolic syndrome and type 2 diabetes. J Lipid Res 2005; 46: 1999-06.
5. Hiukka A, Stahlman M, Pettersson C et al. ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan. Diabetes 2009; 58: 2018-26.
6. Hulthe J, Bokemark L, Wikstrand J, Fagerberg B. The metabolic syndrome, LDL particle size, and atherosclerosis: the Atherosclerosis and Insulin Resistance (AIR) study. Arterioscler Thromb Vasc Biol 2000; 20: 2140-7.
7. Pettersson C, Fogelstrand L, Rosengren B et al. Increased lipolysis by secretory phospholipase A(2) group V of lipoproteins in diabetic dyslipidaemia. J Intern Med 2008; 264: 155-65.
8. Lee SJ, Campos H, Moye LA, Sacks FM. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol 2003; 23: 853-8.
9. Karlsson H, Leanderson P, Tagesson C, Lindahl M. Lipoproteomics I: mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2005; 5: 551-65.
10. Mancone C, Amicone L, Fimia GM et al. Proteomic analysis of human very low-density lipoprotein by two-dimensional gel electrophoresis and MALDI-TOF/TOF. Proteomics 2007; 7: 143-54.
11. Vaisar T, Pennathur S, Green PS et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007; 117: 746-56.
12. Carbonneau MA, Cartron E, Leger CL, Senglat C, Descomps B. New insight on the relationship between LDL composition, associated proteins, oxidative resistance and preparation procedure. Free Radic Res 2002; 36: 127-42.
13. Stahlman M, Davidsson P, Kanmert I et al. Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr. J Lipid Res 2008; 49: 481-90.
14. Bucala R, Makita Z, Vega G et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci U S A 1994; 91: 9441-5.
15. Dekker JM, Girman C, Rhodes T et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005; 112: 666-73.
16. Brohall G, Behre CJ, Hulthe J, Wikstrand J, Fagerberg B. Prevalence of diabetes and impaired glucose tolerance in 64-year-old Swedish women: experiences of using repeated oral glucose tolerance tests. Diabetes Care 2006; 29: 363-7.
17. Bingley PJ, Bonifacio E, Mueller PW. Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 2003; 52: 1128-36.
18. O'Neal D, Harrip P, Dragievic G, Rae D, Best JD. A comparison of LDL size determination using gradient gel electrophoresis and light-scattering methods. J Lipid Res 1998; 39: 2086-90.
19. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957; 226: 497-509.
20. Homan R, Anderson MK. Rapid separation and quantitation of combined neutral and polar lipid classes by high-performance liquid chromatography and evaporative light-scattering mass detection. J Chromatogr B Biomed Sci Appl 1998; 708: 21-6.
21. Hallberg C, Haden M, Bergstrom M et al. Lipoprotein fractionation in deuterium oxide gradients: a procedure for evaluation of antioxidant binding and susceptibility to oxidation. J Lipid Res 1994; 35: 1-9.
22. Ghafouri B, Irander K, Lindbom J, Tagesson C, Lindahl M. Comparative proteomics of nasal fluid in seasonal allergic rhinitis. J Proteome Res 2006; 5: 330-8.
23. Carlsohn E, Nystrom J, Karlsson H, Svennerholm AM, Nilsson CL. Characterization of the outer membrane protein profile from disease-related Helicobacter pylori isolates by subcellular fractionation and nano-LC FT-ICR MS analysis. J Proteome Res 2006; 5: 3197-204.
24. Olofsson SO, Bostrom K, Svanberg U, Bondjers G. Isolation and partial characterization of a polypeptide belonging to apolipoprotein B from low-density lipoproteins of human plasma. Biochemistry 1980; 19: 1059-64.
25. Kapron JT, Hilliard GM, Lakins JN et al. Identification and characterization of glycosylation sites in human serum clusterin. Protein Sci 1997; 6: 2120-33.
26. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A 1993; 90: 6434-8.
27. Huebschmann AG, Regensteiner JG, Vlassara H, Reusch JE. Diabetes and advanced glycoxidation end products. Diabetes Care 2006; 29: 1420-32.
28. Kilhovd BK, Berg TJ, Birkeland KI, Thorsby P, Hanssen KF. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 1999; 22: 1543-8.
29. Li YM, Tan AX, Vlassara H. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nat Med 1995; 1: 1057-61.
30. Mitsuhashi T, Li YM, Fishbane S, Vlassara H. Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix. J Clin Invest 1997; 100: 847-54.
31. Karlsson H, Mörtstedt H, Lindqvist H, Tagesson C, Lindahl M. Protein profiling of low-density lipoprotein from obese subjects. Proteomics Clin Appl 2009; 3: 663-71.
32. Schwarz M, Spath L, Lux CA et al. Potential protective role of apoprotein J (clusterin) in atherogenesis: binding to enzymatically modified low-density lipoprotein reduces fatty acid-mediated cytotoxicity. Thromb Haemost 2008; 100: 110-8.
33. Ibdah JA, Lund-Katz S, Phillips MC. Molecular packing of high-density and low-density lipoprotein surface lipids and apolipoprotein A-I binding. Biochemistry 1989; 28: 1162-33.
34. Chavan V, Patil N, Karnik ND. Study of leukocytic hydrolytic enzymes in patients with acute stage of coronary heart disease. Indian J Med Sci 2007; 61: 73-82.
35. Hansen NE, Karle H. Elevated plasma lysozyme in Hodgkin's disease. An indicator of increased macrophage activity?. Scand J Haematol 1979; 22: 173-8.
36. Torsteinsdottir I, Hakansson L, Hallgren R, Gudbjornsson B, Arvidson NG, Venge P. Serum lysozyme: a potential marker of monocyte/macrophage activity in rheumatoid arthritis. Rheumatology (Oxford) 1999; 38: 1249-54.
37. Erdag G, Morgan JR. Interleukin-1alpha and interleukin-6 enhance the antibacterial properties of cultured composite keratinocyte grafts. Ann Surg 2002; 235: 113-24.
38. Lewis CE, McCarthy SP, Lorenzen J, McGee JO. Differential effects of LPS, IFN-gamma and TNF alpha on the secretion of lysozyme by individual human mononuclear phagocytes: relationship to cell maturity. Immunology 1990; 69: 402-8.
39. Pitsavos C, Tampourlou M, Panagiotakos DB et al. Association between low-grade systemic inflammation and Type 2 Diabetes mellitus among Men and women from the ATTICA Study. Rev Diabet Stud 2007; 4: 98-104.
40. Matsui T, Okomura K, Toki Y, Hayakawa T. Low-Density Lipoprotein Particle Size as an Independent Predictor of Glycated Low-Density Lipoprotein Level. Diabetes Care 1999; 22: 1220-1.
41. Younis N, Charlton-Menys V, Sharma R, Soran H, Durrington PN. Glycation of LDL in non-diabetic people: Small dense LDL is preferentially glycated both in vivo and in vitro. Atherosclerosis 2009; 202: 162-8.
42. Liu H, Zheng F, Li Z et al. Reduced acute vascular injury and atherosclerosis in hyperlipidemic mice transgenic for lysozyme. Am J Pathol 2006; 169: 303-13.
43. Liu H, Zheng F, Cao Q et al. Amelioration of oxidant stress by the defensin lysozyme. Am J Physiol 2006; 290: E824-32.
44. Kujiraoka T, Hattori H, Miwa Y et al. Serum apolipoprotein j in health, coronary heart disease and type 2 diabetes mellitus. J Atheroscler Thromb 2006; 13: 314-22.
45. Navab M, Anantharamaiah GM, Reddy ST et al. An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2005; 25: 1932-7.
46. Navab M, Hama-Levy S, Van LentenBJ et al. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest 1997; 99: 2005-19.